LGD-4033 

Ligandrol was developed to increasing lean muscle, improve strength, and prevent muscle wastage.

Qty: 30 tablets

EACH TABLET CONTAINS 25MG OF LGD 4033 

Supplied for Research Purposes Only

This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.

Benefits and uses:

Increases the rate at which muscle is built.

Strength and endurance are both improved.

Helps reduce fat for improved definition.

Increases bone density and density overall.

Mild, and it has a low risk of harm

Dose:

25mg per day

What is LGD 4033?

LGD 4033, also known as the more common name Ligandrol, is currently one of the performance enhancing chemicals that are in the highest demand on the market. In its most basic form, it is a recently produced selective androgen receptor modulator that primarily attracts bodybuilders who are interested in achieving a larger than normal body. However, aesthetics were in no way a factor in the decision to create it in the first place. 

Because it mimics the effects of the anabolic hormone testosterone, LGD 4033 was developed with the intention of being used in medicinal applications. This involves treating the degradation of the muscles and bones that is caused by medical disorders such as osteoporosis and muscle wasting. However, due to the fact that the supplement has the potential to improve bone density and muscle mass, it gained popularity as a fitness drug.

Some of the negative aspects of LGC 4033:

Could require PCT

It is a medication that is currently under study.

Researchers are looking into the possibility of using a chemical that was recently made available by Ligand Pharmaceuticals as a treatment for a variety of illnesses, including age-related frailty. It does not currently possess an approval for use in or out of contests from either the Food and Drug Administration or the World Anti-Doping Agency. In spite of this, a significant number of people use Ligandrol in order to bulk up, improve their athletic ability, and get an advantage over their rivals.

How LGD 4033 work?

The action mechanism of ligandrol is one-of-a-kind and shares no parallels at all with that of anabolic steroids. As a consequence of this, it has effects that are relatively light and less hazardous to the health of the people who use it.

As is the case with every other type of SARM, it binds to and stimulates the androgen receptors that are present in the skeletal and muscular tissues. Androgens are a class of hormones that play a significant role in the development of male sexual characteristics. As a result, its effects are favourable for bulk gainers and athletes in the same way that testosterone's effects are.

When LGD 4033 binds to androgen receptors, it boosts the activity of anabolic enzymes, which results in increased muscle growth. This, in turn, stimulates the growth of muscles, increases strength, and fortifies the bones in your body.

In what ways is LGD 4033 beneficial to users?

LGD 4033 is a flexible and can be used to help achieve a wide variety of fitness-related aims in a short amount of time. However, putting on mass is the most important aspect of using the supplement.

Indeed, Ligandrol is intended to target and encourage the growth and development of muscles, which will ultimately result in a larger and more robust frame. Nevertheless, the synthesis of raw mass is not the only purpose served by the use of Ligandrol!

There is much to learn about this chemical that improves performance. In essence, it is helpful in the following ways:

Increase in bulk that is leaner and free of fat.

Increases in power production, muscularity, and endurance

Promotes fat reduction, which in turn helps the muscle chiselling process.

Increases bone density and helps to avoid muscle atrophy

Strength and stamina are both improved as a result.

Enhances both the mental health and performance of the user.

Helps in the recovery from workout exhaustion

Effects that are truly remarkable for building muscle

LGD 4033 is a relatively new drug that has been developed to combat the use of anabolic steroids, which have been commonplace in the fitness industry for decades. People have voiced their delight and preference for the safety of it, despite the fact that it was just recently introduced into the community of mass gainers.

The majority of users are really satisfied with the effects that it has on increasing the size of their muscles. These users are either in the beginning stages of bodybuilding or have progressed to the advanced level. This suggests that the drug is beneficial in increasing and developing bulk for both amateurs and professionals alike.

According to feedback, Ligandrol is the secret to quickly gaining muscle mass and is an excellent choice for use during bulking cycles. Every person who goes to the gym can expect to gain from it, but those who are looking for genuine results will benefit the most. Although many people praised it for its effectiveness as a standalone agent, others asserted that they derived greater advantages from stacking it with ostarine MK 2866.

Ligandrol is effective not just in increasing size, but also in enhancing one's physical performance by significantly increasing one's strength. Many people believe that it can help extend your training time without causing you to feel weary or frustrated as quickly as might otherwise be the case.

The supplement receives generally positive reviews and comes highly recommended by users who have had direct experience with it. Nearly everyone has found it gratifying for their fitness goals, ranging from increased muscle growth to breaking through previously established muscle-building plateaus. However, they feel that the most distinctive advantage that can be associated with Ligandrol is the ability to construct "cleaner" or, to put it another way, fat-free muscles.

As an illustration, male bodybuilders can begin their dosage somewhere between 10 and 20 milligrammes per day. It is recommended that women start with a lower dosage, between 5 and 10 milligrammes per day.

According to the assertions of certain medical experts, the correct dosage for you will change depending on the stage you are currently in. That example, 10 milligrammes per day is a good starting point for novices. People who are at an intermediate level are able to safely consume 15 mg per day, however the daily dosage that is recommended for experts is 20 mg.

CONCLUSION:

Ligandrol has an excellent track record as a medication that improves athletic performance in general. The vast majority of people are comfortable stating that they will include the substance in both their bulking and cutting cycles. In addition, when used in conjunction with MK-677, it yields exceptionally impressive effects. On the other hand, if you are looking to cut down as part of your exercise routine, you should consider stacking it with S4 or Cardarine.

References:

1. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107:123–136. [PubMed] [Google Scholar]

2. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002;283:E284–E294. [PubMed] [Google Scholar]

3. Melton LJ, III, Khosla S, Crowson CS, O’Connor MK, O’Fallon WM, Riggs BL. Epidemiology of sarcopenia. J Am Geriatr Soc. 2000;48:625–630. [PubMed] [Google Scholar]

4. Bassey EJ, Fiatarone MA, O’Neill EF, Kelly M, Evans WJ, Lipsitz LA. Leg extensor power and functional performance in very old men and women. Clin Sci (Lond) 1992;82:321–327. [PubMed] [Google Scholar]

5. Lexell J, Downham D, Sjostrom M. Distribution of different fibre types in human skeletal muscles. A statistical and computational study of the fibre type arrangement in m. vastus lateralis of young, healthy males. J Neurol Sci. 1984;65:353–365. [PubMed] [Google Scholar]

6. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166:2124–2131. [PubMed] [Google Scholar]

7. Morely JE, Thomas DR. Cachexia: new advances in the management of wasting diseases. J Am Med Dir Assoc. 2006;9(4):205–210. [PubMed] [Google Scholar]

8. Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Practice Endocrinol Metab. 2006;2:146–159. [PMC free article] [PubMed] [Google Scholar]

9. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1–7. [PubMed] [Google Scholar]

10. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639–650. [PubMed] [Google Scholar]

11. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502–1510. [PubMed] [Google Scholar]

12. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–2677. [PubMed] [Google Scholar]

13. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–688. [PubMed] [Google Scholar]

14. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88:1478–1485. [PubMed] [Google Scholar]

15. Travison TG, Basaria S, Storer TW, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66:1090–1099. [PMC free article] [PubMed] [Google Scholar]

16. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6 [PMC free article] [PubMed] [Google Scholar]

17. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2:153–161. [PMC free article] [PubMed] [Google Scholar]

18. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148:363–373. [PubMed] [Google Scholar]

19. Schmidt A, Kimmel DB, Bai C, et al. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010;285:17054–17064. [PMC free article] [PubMed] [Google Scholar]

20. LeBrasseur NK, Bhasin S, Miciek R, Storer TW. Tests of muscle strength and physical function: reliability and discrimination of performance in younger and older men and older men with mobility limitations. J Am Geriatr Soc. 2008;56:2118–2123. [PMC free article] [PubMed] [Google Scholar]

21. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–122. [PMC free article] [PubMed] [Google Scholar]

22. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine. Principles and Practice of Kinetic Analysis. New York, NY: Wiley-Liss; 1992. [Google Scholar]

23. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430–2439. [PMC free article] [PubMed] [Google Scholar]

24. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74:512–519. [PubMed] [Google Scholar]

25. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24:183–217. [PubMed] [Google Scholar]

26. Schroeder ET, Singh A, Bhasin S, et al. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Am J Physiol Endocrinol Metab. 2003;284:E120–E128. [PubMed] [Google Scholar]

27. Thompson PD, Cullinane EM, Sady SP, Chenevery C, Saritelli AL, Sady MA. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261:1165–1168. [PubMed] [Google Scholar]

28. von Eckardstein A, Nofer JR, Assmann G. HDL and coronary heart disease: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;20:13. [PubMed] [Google Scholar]

29. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising of HDL cholesterol? Curr Opin Lipidol. 2000;11:627–663. [PubMed] [Google Scholar]

30. Tang J, Srivastava RAK, Krul ES, et al. In vivo regulation of apolipoprotein A-I gene expression by estradiol and testosterone occurs by different mechanisms in inbred strains of mice. J Lipid Res. 1991;32:1571–1585. [PubMed] [Google Scholar]

31. Krieger M. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523–555. [PubMed] [Google Scholar]

32. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296:1051–1057. [PubMed] [Google Scholar]

33. Glueck CJ, Gartside P, Fallat RW, Mendoza S. Effect of sex hormones on protamine inactivated and resistant postheparin plasma lipase. Metabolism. 1976;25:625–630. [PubMed] [Google Scholar]

34. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283:E154–E164. [PubMed] [Google Scholar]

35. Ibebunjo C, Eash JK, Li C, Ma Q, Glass DJ. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement. Am J Physiol Endocrinol Metab. 2011;300:E327–E340. [PubMed] [Google Scholar]

36. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269(5 Pt 1):E820–E826. [PubMed] [Google Scholar]

37. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–E607. [PubMed] [Google Scholar]

38. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003;285:E197–E205. [PubMed] [Google Scholar]

39. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144:5081–5088. [PubMed] [Google Scholar]

40. Serra C, Bhasin S, Tangherlini F, et al. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology. 2011;152:193–206. [PMC free article] [PubMed] [Google Scholar]